ClinicalTrials.gg
RecruitingNCT06727409RAiSiNUpdated Mar 5, 2025

Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease

A Phase 4 interventional study of Finerenone in Patients With Type 2 Diabetes, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by Chinese University of Hong Kong · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing finerenone in Diabetes Mellitus, Type 2 — 5 open to participants now, 6 under way, none of them phase 3. finerenone · Diabetes Mellitus, Type 2.

Planned enrollment
10th of 13
82 · median 100
Started
2024
with 3 others
Phase 4
7 of 13
4 open now
Registered
9th of 13
by date
Lead sponsor
1 of 13
Chinese University of Hong Kong

Among the 13 studies testing finerenone in Diabetes Mellitus, Type 2, this one is the 10th largest by planned enrollment, is one of 4 that started in 2024, is one of 7 in phase 4, and was the 9th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 13 studies testing finerenone in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing finerenone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To evaluate triple therapy with nsMRA, RASi and SGLT2i on albuminuria in individuals with T2D and CKD

03

Conditions studied

  • Patients With Type 2 Diabetes

Keywords

  • Finereone, Triple therapy, Type 2 Diabetes, Chronic kidney disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or above
  • Diagnosis of type 2 diabetes at least 6 months
  • CKD ( by CKD-EPI 25-90 ml/min/1.73m2 with uACR 30 to \<300 mg/g) and/or those with severely elevated albuminuria (uACR 30-5000 mg/g) and eGFR > 60 ml/min/1.73m2.
  • Patients should have a serum potassium \<4.8 mmol/l at screening
  • On SGLT2i (dapagliflozin or empaglifozin) at screening at stable doses for at least 4 weeks.
  • On ACEi or ARB at maximum tolerated dose per manufacturer's label that did not cause unacceptable side effects
  • In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a suitable study candidate.

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes
  • Allergy, or intolerance to ACEi/ARB
  • Contraindications or intolerance to mineralocorticoid receptor antagonists
  • Allergy, contraindications to SGLT2is
  • Currently pregnant or planning pregnancy
  • >9% at enrolment
  • Uncontrolled hypertension SBP > 160mmHg or hypotension \<90 mmHg at enrolment
  • Concomitant therapy with eplenerone, spironolactone that cannot be discontinued.
  • History of stroke or worsening heart failure in the past 6 months prior to screening
  • Diabetic ketoacidosis, hyperosmolar hyperglycaemic state or myocardial infarction in the six months prior to screening
  • Patients on renal replacement therapy or likely require kidney transplant or dialysis during the study period
  • On concomitant strong inhibitors that cannot be discontinued
  • Adrenal insufficiency
  • Currently participating in another study protocol where the testing or results may interfere with study compliance, diagnostic results, or data collection.
  • An identified protected vulnerable patient (including but not limited to those in detention, or a prisoner).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    Finerenone on top of maximal tolerated RASi and stable SGLT2i therapy

    pre and post Finerenone treatment evaluation

    Drug: Finerenone

Interventions

  • Finerenone 10mg or 20 mg as tolerated on top of maximal tolerated RASi and stable SGLT2i therapy

06

What researchers measure

Primary outcomes

  1. Change in urine albumin creatinine ratio (uACR)

    urine ACR between baseline and end of study (26 weeks)

    Time frame: 26 weeks

Secondary outcomes

  1. Change in estimated glomerular filtration rate (eGFR)

    eGFR calculated from plasma creatinine from baseline to end of study in ml/min/1.73m2

    Time frame: 26 weeks

  2. Change in potassium

    Change in plasma potassium (mmol/l) from baseline to end of study

    Time frame: 26 weeks

  3. Change in blood pressure

    Change in systolic and diastolic blood pressure (mmHg) from baseline to end of study

    Time frame: 26 weeks

  4. Change in heath related quality of life

    change in HRQoL from baseline to end of study using EQ5D

    Time frame: 26 weeks

  5. Change in body weight

    Change in body weight (kg) from baseline to end of study

    Time frame: 26 weeks

07

Study locations

1 of 1 sites recruiting
  • 3M, Diabetes and Endocrine Research Center
    Hong Kong, Hong Kong
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jul 2026, 19 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 19 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2024
First posted
Dec 10, 2024
StartActual
Dec 12, 2024
Primary completionEst.
Jul 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06727409
Responsible party
Elaine Chow (Clinical Associate Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Dec 10, 2024
Start date
Dec 12, 2024
Primary completion
Jul 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 5, 2025

Study contacts

Elaine Chow
Contact
e.chow@cuhk.edu.hk
+852 35051641

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion